Vectors in gene therapy

Solve GNE and Gradalis Sign Agreement to Develop a Novel Gene Therapy Targeting HIBM

Retrieved on: 
Monday, July 31, 2023
DNA, GNE, Myopathy, Mutation, Research, Muscle weakness, Incidence, Patient, HIBM, FDA, IND, Vectors in gene therapy, Safety, Disease, Vaccine, Pharmaceutical industry

LOS ANGELES, July 31, 2023 (GLOBE NEWSWIRE) -- Solve GNE announced today that it has entered into a sponsored research agreement with Gradalis, Inc. to provide funding for a novel lipid nanoparticle gene therapy aimed at curing GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM).

Key Points: 
  • LOS ANGELES, July 31, 2023 (GLOBE NEWSWIRE) -- Solve GNE announced today that it has entered into a sponsored research agreement with Gradalis, Inc. to provide funding for a novel lipid nanoparticle gene therapy aimed at curing GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM).
  • GNE Myopathy is a muscular disorder caused by an inherited mutation of a muscle support gene called GNE.
  • Gradalis’ earlier human phase 1 data1 indicate that multiple systemic infusions of a GNE- Lipoplex2 into a patient with advanced GNE Myopathy were generally tolerable and safe.
  • 2 Nemunaitis, G., et al., Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplex.

GoComet launches Advanced Predictive ETA, GoPlan & Proactive Upload: Step into the future

Retrieved on: 
Wednesday, September 14, 2022
ETA, Proactivity, Risk, ETAS, Solution, BL, Goplans, Software as a service, Customer advisory council, Cassette tape, Cargo, Vectors in gene therapy

SINGAPORE, Sept. 14, 2022 /PRNewswire/ -- GoComet, a leading multi-modal logistics and transportation company, has launched a breakthrough product, 'GoPlan', one of the first data-backed dispatch planning solutions that will allow shippers to plan their freight delivery schedules with better predictability using one of the the industry's best estimate lead time benchmarking indexes. It will help shippers promise realistic delivery ETAs to end consignees when shipping containers worldwide. The company aims to solve one of the biggest challenges prevailing in the supply chain industry – Inaccurate Carrier ETAs. Alongside, it chooses the best performing carrier that is economical, effective and helps in delivering as planned with less risk for customers.  

Key Points: 
  • The company aims to solve one of the biggest challenges prevailing in the supply chain industry Inaccurate Carrier ETAs.
  • Alongside, it chooses the best performing carrier that is economical, effective and helps in delivering as planned with less risk for customers.
  • In addition to the new product, GoComet announced a major platform upgrade , because getting notified after a shipment gets delayed is a thing of the past.
  • Trusted by 200+ global brands across 35 countries, GoComet is currently headquartered in Singapore and has a presence in Southeast Asia, the US and Europe.

GoComet launches Advanced Predictive ETA, GoPlan & Proactive Upload: Step into the future

Retrieved on: 
Wednesday, September 14, 2022
ETA, Proactivity, Risk, ETAS, Solution, BL, Goplans, Software as a service, Customer advisory council, Cassette tape, Cargo, Vectors in gene therapy

SINGAPORE, Sept. 14, 2022 /PRNewswire/ -- GoComet, a leading multi-modal logistics and transportation company, has launched a breakthrough product, 'GoPlan', one of the first data-backed dispatch planning solutions that will allow shippers to plan their freight delivery schedules with better predictability using one of the the industry's best estimate lead time benchmarking indexes. It will help shippers promise realistic delivery ETAs to end consignees when shipping containers worldwide. The company aims to solve one of the biggest challenges prevailing in the supply chain industry – Inaccurate Carrier ETAs. Alongside, it chooses the best performing carrier that is economical, effective and helps in delivering as planned with less risk for customers.  

Key Points: 
  • The company aims to solve one of the biggest challenges prevailing in the supply chain industry Inaccurate Carrier ETAs.
  • Alongside, it chooses the best performing carrier that is economical, effective and helps in delivering as planned with less risk for customers.
  • In addition to the new product, GoComet announced a major platform upgrade , because getting notified after a shipment gets delayed is a thing of the past.
  • Trusted by 200+ global brands across 35 countries, GoComet is currently headquartered in Singapore and has a presence in Southeast Asia, the US and Europe.

Global and Chinese Viral Vectors and Plasmid DNA Manufacturing Markets, 2016-2020 & 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, May 17, 2021
Other Science, Science, Branches of biology, Biology, Gene delivery, Molecular biology, Biochemistry, Plasmid, Vector, Viral vector, Vectors in gene therapy

b'The "Global and Chinese Viral Vectors and Plasmid Dna Manufacturing Industry, 2021 Market Research Report" report has been added to ResearchAndMarkets.com\'s offering.\n\'Global and Chinese Viral Vectors and Plasmid DNA Manufacturing Industry, 2021 Market Research Report\' is a professional and in-depth study on the current state of the global Viral Vectors and Plasmid DNA Manufacturing industry with a focus on the Chinese market.\nThe report provides key statistics on the market status of the Viral Vectors and Plasmid DNA Manufacturing manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.\nFirstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology.

Key Points: 
  • b'The "Global and Chinese Viral Vectors and Plasmid Dna Manufacturing Industry, 2021 Market Research Report" report has been added to ResearchAndMarkets.com\'s offering.\n\'Global and Chinese Viral Vectors and Plasmid DNA Manufacturing Industry, 2021 Market Research Report\' is a professional and in-depth study on the current state of the global Viral Vectors and Plasmid DNA Manufacturing industry with a focus on the Chinese market.\nThe report provides key statistics on the market status of the Viral Vectors and Plasmid DNA Manufacturing manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.\nFirstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology.
  • In this part, the report presents the company profile, product specifications, capacity, production value, and 2016-2021 market shares for each company.\nThrough statistical analysis, the report depicts the global and Chinese total market of Viral Vectors and Plasmid DNA Manufacturing industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.
  • The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.\nThe report then estimates 2021-2026 market development trends of the Viral Vectors and Plasmid DNA Manufacturing industry.
  • In the end, the report makes some important proposals for a new project of the Viral Vectors and Plasmid DNA Manufacturing Industry before evaluating its feasibility.\nOverall, the report provides an in-depth insight of the 2021 global and Chinese Viral Vectors and Plasmid DNA Manufacturing industry covering all important parameters.\n'

SalioGen Therapeutics Announces Closing of $20 Million Series A Financing to Support Advancing a Novel Genome Engineering Platform for Non-Viral Gene Therapy

Retrieved on: 
Monday, March 1, 2021
Branches of biology, Biology, Life sciences, Emerging technologies, Biotechnology, Molecular biology, Genetic engineering, Gene delivery, Gene therapy, Genome editing, Genome, Vectors in gene therapy

In conjunction with the financing, SalioGen has strengthened its Board of Directors and its Scientific Advisory Board.

Key Points: 
  • In conjunction with the financing, SalioGen has strengthened its Board of Directors and its Scientific Advisory Board.
  • SalioGen has assembled a prestigious leadership team with collective experience in human gene therapy, medical genetics, lipid nanoparticles and cell therapy.
  • SalioGen is developing EDIT, a genome engineering technology based on the mammal-derived enzyme saliogase.
  • SalioGen Therapeutics is advancing the Exact DNA Integration Technology (EDIT) platform, the only genome engineering technology that is mammal-derived, for use in potentially curative non-viral gene therapy.

Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology Insights Report 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 27, 2021
Health, Genetics, Branches of biology, Biology, Gene delivery, Medical genetics, Applied genetics, Emerging technologies, Molecular biology, Adeno-associated virus, Viral vector, Vectors in gene therapy, Gene therapy, AAV

The "Adeno-Associated Virus (AAV) Vectors in Gene Therapy - Epidemiology Insight - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Adeno-Associated Virus (AAV) Vectors in Gene Therapy - Epidemiology Insight - 2030" report has been added to ResearchAndMarkets.com's offering.
  • This 'Adeno-Associated Virus (AAV) Vector Based Gene Therapy- Epidemiology Forecast to 2030' report delivers an in-depth understanding of the AAV vector based gene therapy across the various therapeutic areas are several selected diseases, historical and forecasted AAV Vector Based Gene Therapy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Gene therapy involves "vectors" which can be either viral or non-viral vectors.
  • rAAV gene therapy strategies include Gene replacement, Gene silencing, Gene addition and Gene editing.

Ixaka (formerly Rexgenero) Launches as an Integrated Cell and Gene Therapy Company

Retrieved on: 
Monday, January 18, 2021
Oncology, Health, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Life sciences, Biology, Biotechnology, Emerging technologies, Molecular biology, Medical genetics, Bioethics, Gene therapy, Therapy, Vectors in gene therapy, Ixaka, Ixaka’s multi-cell therapies, Ixaka’s in vivo gene delivery technology

Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of the body to cure disease, launches today.

Key Points: 
  • Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of the body to cure disease, launches today.
  • Joe Dupere, CEO of Ixaka, commented: Ixakas broad offering of integrated cell and gene therapy capabilities, encompassing cell-based products and an innovative in vivo gene delivery platform, provides a strong foundation for our ambitions to become a leader in cell and gene therapies.
  • Our focus is now on accelerating progress to help realise the potential for durable and curative cell and gene therapies.
  • Ixaka is a cell and gene therapy company focused on using the natural powers of the body to cure disease.

DGAP-News: ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy

Retrieved on: 
Monday, January 18, 2021
Branches of biology, Biology, Life sciences, Applied genetics, Gene delivery, Medical genetics, Emerging technologies, Molecular biology, Daiichi Sankyo, Adeno-associated virus, Vectors in gene therapy, Gene therapy

The companies will evaluate ViGeneron's proprietary, intravitreally injected vgAAV vectors for delivering a novel therapeutic protein to develop a gene therapy treatment for a highly prevalent eye disease

Key Points: 
  • The companies will evaluate ViGeneron's proprietary, intravitreally injected vgAAV vectors for delivering a novel therapeutic protein to develop a gene therapy treatment for a highly prevalent eye disease
    Munich, Germany, January 18, 2021 - ViGeneron GmbH, a gene therapy company, today announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited ("Daiichi Sankyo"), for delivering a novel therapeutic protein to address an undisclosed target in a highly prevalent ophthalmic disease.
  • ViGeneron's innovative gene therapy expertise combined with Daiichi Sankyo's ophthalmic knowledge creates the potential to develop a sustained novel gene therapy to overcome the current limitations in treating this highly prevalent ophthalmic disease," commented Dr. Caroline Man Xu, Co-founder and CEO of ViGeneron.
  • Under the agreement, Daiichi Sankyo and ViGeneron will jointly conduct the first stage research and Daiichi Sankyo will have the option to negotiate a follow-on collaboration agreement for an undisclosed therapeutic target in the highly prevalent eye disease.
  • The first, vgAAV gene therapy vector platform, allows superior transduction efficiency and intravitreal, a less invasive treatment administration.

ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy

Retrieved on: 
Monday, January 18, 2021
Branches of biology, Biology, Life sciences, Applied genetics, Medical genetics, Gene delivery, Emerging technologies, Molecular biology, Daiichi Sankyo, Adeno-associated virus, Gene therapy, Vectors in gene therapy

MUNICH, Germany, Jan. 18, 2021 (GLOBE NEWSWIRE) -- ViGeneron GmbH, a gene therapy company, today announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited (Daiichi Sankyo), for delivering a novel therapeutic protein to address an undisclosed target in a highly prevalent ophthalmic disease.

Key Points: 
  • MUNICH, Germany, Jan. 18, 2021 (GLOBE NEWSWIRE) -- ViGeneron GmbH, a gene therapy company, today announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited (Daiichi Sankyo), for delivering a novel therapeutic protein to address an undisclosed target in a highly prevalent ophthalmic disease.
  • ViGenerons innovative gene therapy expertise combined with Daiichi Sankyos ophthalmic knowledge creates the potential to develop a sustained novel gene therapy to overcome the current limitations in treating this highly prevalent ophthalmic disease, commented Dr.Caroline Man Xu, Co-founder and CEO of ViGeneron.
  • Under the agreement, Daiichi Sankyo and ViGeneron will jointly conduct the first stage research and Daiichi Sankyo will have the option to negotiate a follow-on collaboration agreement for an undisclosed therapeutic target in the highly prevalent eye disease.
  • The first, vgAAV gene therapy vector platform, allows superior transduction efficiency and intravitreal, a less invasive treatment administration.

DGAP-News: CEVEC signs agreement with Roche for the use of CEVEC's ELEVECTA(R) Technology in gene therapy

Retrieved on: 
Tuesday, November 10, 2020
Branches of biology, Biology, Gene delivery, Life sciences, Molecular biology, Biotechnology, Applied genetics, Emerging technologies, Viral vector, Oncolytic virus, Vectors in gene therapy, Gene therapy, ELEVECTA(R), AAV Gene Therapy Vectors, CEVEC

The partnership will provide Roche the rights to use CEVEC's technology for their portfolio of gene therapy products.

Key Points: 
  • The partnership will provide Roche the rights to use CEVEC's technology for their portfolio of gene therapy products.
  • "We are delighted to partner with Roche with the goal to manufacture AAV vector-based gene therapy programs on a large scale by leveraging our novel ELEVECTA(R) Technology.
  • The ELEVECTA(R) Technology is a new technology platform developed and marketed by CEVEC for the production of AAV gene therapy vectors.
  • The company's product portfolio comprises platform technologies for gene therapy viral vectors (AAV, Adeno, Oncolytic viruses) and complex recombinant proteins.